Bli medlem
Bli medlem

Du är här


Immune Pharmaceuticals: Immune Pharmaceuticals Provides Business and R&D Update and Announces First Quarter 2016 Financial Results


Immune Pharmaceuticals Inc. (NASDAQ:IMNP) ("Immune" or the "Company")
announced financial results for the first quarter ended March 31, 2016.

Business and Research & Development ("R&D") Update

Immune continues to pursue its strategy to unlock the value of its
diversified pipeline through the development, financing and strategic
partnering of specifically focused asset groups:

* Immuno-inflammation focus on gastro-enterology and dermatology
through a pipeline comprised of two assets: bertilimumab, currently
in two phase II clinical trials in ulcerative colitis and bullous
pemphigoid with a third phase II planned in severe atopic dermatitis,
and topical nano-formulated cyclosporine for the treatment of atopic
dermatitis and psoriasis.
* Immuno-oncology subsidiary that includes three mid-to-late stage
clinical assets (Ceplene®, Azixa®, Crolibulin®) as well as novel
platforms: bispecific antibodies and NanomAbs ®, antibody
nanoparticle conjugates.
* The licensing of AmiKet® and AmiKet® Nano for the treatment of
peripheral neuropathic pain to a newly-created pain specialty pharma
company: Immune executed an exclusive 60-day option with Novel Pain
Therapeutics ("NPT") to enter into a worldwide license agreement for
AmiKet and AmiKet Nano for the treatment of peripheral neuropathic
pain. Upon execution of the license agreement pursuant to agreed
material terms in the option, NPT will assume all research and
development costs and Immune will be eligible to receive up to $160
million, comprised of an upfront fee of at least $15 million in the
form of equity in NPT, up to $25 million in development milestones,
and up to $120 million in commercial milestones, as well as product
sales royalties. Immune will also be eligible to receive 25% and up
to 50% of sublicense fees received by NPT.

Immune continues to execute its R&D plan with progress for all its key

* Continued enrollment into the two Phase II clinical trials with
* Publication in Oncotarget and presentation at the American Academy of
Cancer Research (AACR) meeting of European phase IV studies
highlighting predictive bio-markers of overall survival in
maintenance of first remission in patients with acute myeloid
leukemia. Immune intends to submit to the Food and Drug
Administration a plan for a pivotal overall survival study with
Ceplene® in combination with low dose IL-2 (Proleukin®).
* On-going development and testing of new bi-specific antibodies
targeting PD-1 and OX40 (two immune check points) and PDL-1 and BCMA
(an immune check point and a tumor marker of multiple myeloma).
* On-going development of topical nano-formulated cyclosporine toward
an investigational new drug application and initiation of 505(b) 2
clinical development.

"We are structuring the Company strategically to ensure long term
comprehensive financing of our product pipeline and enable focused
execution" said Dr. Daniel Teper, CEO of Immune Pharmaceuticals Inc. "We
continue to progress in our clinical trials with bertilimumab as we
increase patient enrollment and we are on track to achieve our operational
and financial objectives for 2016."

For the complete report see attached document.

NEW YORK, May 16, 2016

For further information:
Danielle Shapira, Manager, Strategic Planning, Immune Pharmaceuticals Inc.,

The following documents can be retrieved from beQuoted
Immune Pharmaceuticals Interim Report Q1 2016.pdf

About Immune Pharmaceuticals Inc.:
Immune Pharmaceuticals Inc., (NASDAQ:IMNP) together with its subsidiaries,
is a clinical stage biopharmaceutical company specializing in the
development and commercialization of novel targeted therapeutics in the
fields of immuno-inflammation and immuno-oncology. The Company focuses on a
precision medicine approach to treatment of diseases by incorporating
methods for better patient selection in its clinical trials and the
potential for development of companion diagnostics. The Company's
immunoinflammation product pipeline includes: bertilimumab, a
clinical-stage first-in-class fully human antibody, targeting eotaxin-1, a
key regulator of immuno-inflammation, a portfolio of clinical-stage immune
oncology products and NanoCyclo, a topical nanocapsule formulation of
cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. For
more information, visit Immune's website at ,
the content of which is not a part of this press release.

Forward-Looking Statements
This news release and any oral statements made with respect to the
information contained in this news release contain forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. You are urged to consider statements that include the words
"may," "will," "would," "could," "should," "believes," "estimates,"
"projects," "potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal" or the negative of those words
or other comparable words to be uncertain and forward-looking. Such
forward-looking statements include statements that express plans,
anticipation, intent, contingency, goals, targets, future development and
are otherwise not statements of historical fact. These statements are based
on our current expectations and are subject to risks and uncertainties that
could cause actual results or developments to be materially different from
historical results or from any future results expressed or implied by such
forward-looking statements. Factors that may cause actual results or
developments to differ materially include, but not limited to: the risks
associated with the adequacy of our existing cash resources and our ability
to continue as a going concern; the risks associated with our ability to
continue to meet our obligations under our existing debt agreements; the
risk that clinical trials for bertilimumab or AmiKet will not be
successful; the risk that bertilimumab, AmiKet or compounds arising from
our NanomAbs program will not receive regulatory approval or achieve
significant commercial success; the risk that we will not be able to find a
partner to help conduct the Phase III trials for AmiKet on attractive
terms, on a timely basis or at all; the risk that our other product
candidates that appeared promising in early research and clinical trials do
not demonstrate safety and/or efficacy in larger-scale or later-stage
clinical trials; the risk that we will not obtain approval to market any of
our product candidates; the risks associated with dependence 3 upon key
personnel; the risks associated with reliance on collaborative partners and
others for further clinical trials, development, manufacturing and
commercialization of our product candidates; the cost, delays and
uncertainties associated with our scientific research, product development,
clinical trials and regulatory approval process; our history of operating
losses since our inception; the highly competitive nature of our business;
risks associated with litigation; and risks associated with our ability to
protect our intellectual property. These factors and other material risks
are more fully discussed in our periodic reports, including our reports on
Forms 8-K, 10-Q, and 10-K and other filings with the U.S. Securities and
Exchange Commission. You are urged to carefully review and consider the
disclosures found in our filings, which are available at
or at . You are cautioned
not to place undue reliance on any forwardlooking statements, any of which
could turn out to be wrong due to inaccurate assumptions, unknown risks or
uncertainties, or other risk factors. We expressly disclaim any obligation
to publicly update any forward looking statements contained herein, whether
as a result of new information, future events or otherwise, except as
required by law.

SOURCE Immune Pharmaceuticals Inc.

Författare BEQ

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.